Modulight news & articles

Modulight news & articles

Modulight Spotlights: LASER-SHARP RESEARCH – September 2023

Modulight Spotlights: LASER-SHARP RESEARCH – September 2023 Head & neck cancer is world’s sixth most common cancer, with increasing incidence and poor survival. A new study by P. Enzian & R. Rahmanzadeh at University of Lübeck, studied combining chemotherapy with photochemical internalization for more effective H&N cancer treatment in vitro. Photochemical internalization using photosensitizer fimaporfin, activated with Modulight’s ML6600 laser, was shown to increase drug’s efficacy by means of better drug delivery inside the cells. As a result, tumor cell death was achieved using 20-fold Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – August 2023

Modulight Spotlights: LASER-SHARP RESEARCH – August 2023 Interleukin 15 (IL-15) is promising candidate for cancer immunotherapy, since it is an inducer of differentiation and proliferation of killer T cells and NK cells. A new study by Fukushima et al. at NCI, published in Molecular Cancer Therapeutics, shows increase in therapeutic efficacy in vivo when IL15 was combined with photoimmunotherapy using ML7710 laser system. Intratumoral injection of IL-15 also boosted the immune responses against both the primary tumor as well as abscopal effect eradicating distant, untreated tumor.​ ​​ Read original publication Modulight Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – April 2023

Modulight Spotlights: LASER-SHARP RESEARCH – April 2023 Metastases remain the leading cause of cancer-related deaths worldwide. To combat this problem, Ruben V. Huis in ‘t Veld et al. combined immune checkpoint inhibitors with a light-activated virus-drug conjugate in their preclinical study. As published in Cancer Immunology, Immunotherapy journal, the combination was effective against metastatic tumors and in most cases even resulted in complete responses to therapy. ​​ Read original publication   Modulight is very happy to be supporting this research. We would like to deliver our Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – February 2023

Modulight Spotlights: LASER-SHARP RESEARCH – February 2023 The nomination for Laser-Sharp Research goes to Mäki-Mikola et al. at University of Helsinki for their development of a dynamic cell culturing platform for light-activation studies. The developed platform has a flow chamber connected to a peristaltic pump, which creates a flow that resembles the natural fluid flow at the cell surfaces. ML6500 laser was used to release calcein from liposomes to validate the suitability of the platform for light-triggered drug release. Compared to traditional static cell culture Continue reading →

Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lombs VISUDYNE (Verteporfin for Injection)

Modulight Investor Contacts: Ulla Haapanen ulla.haapanen@modulight.com (408) 218-7960 Modulight Media Contacts: Zoe Ylöniemi zoe.yloniemi@modulight.com (408) 239-3488 Bausch + Lomb Investor Contacts: Arthur Shannon/Allison Ryan arthur.shannon@bausch.com allison.ryan@bausch.com (877) 354-3705 (toll free); (908) 927-0735 Bausch + Lomb Media Contacts: Lainie Keller/Kristy Marks lainie.keller@bausch.com kristy.marks@bausch.com (908) 927-1198; (908) 927-0683 Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection) VAUGHAN, Ontario and TAMPERE, Finland, Feb. 1, 2023 – Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – December 2022

Modulight Spotlights: LASER-SHARP RESEARCH – December 2022 This month’s research spotlight goes to H. Wakiyama, H. Kobayashi, et al. at National Cancer Institute, USA. Their study, published in Cancer Immunology Research journal, looked into immunological mechanisms behind hyperprogressive disease. Immune checkpoint inhibitors, despite being a major success story in the field of cancer therapy, unfortunately lead to this rapid progression of cancer in some patients, for yet poorly understood reasons. To study this, the research team partially depleted cytotoxic T cells by photoimmunotherapy, using CD8-targeted Continue reading →

GET THE LATEST FROM MODULIGHT.

We are sending newsletters occasionally, a few times per year. We are sharing news and events, sometimes also interesting scientific publications. Each newsletter has an unsubscribe link so you won’t be trapped with the subscription if you change your mind. Ready to subscribe?

*

Press releases archive



2010–2015

16 Sep 2015 Rising star in immunotherapy competition »

28 Jan 2015 Modulight launches the world’s first multi indication CE and ETL certified medical laser »

09 Sep 2014 Modulight ML7710-PDT laser platform CB testing completed »

30 Jan 2014 Modulight broadens their OEM laser system family to single-mode and multi-wavelength laser modules »

14 Nov 2013Modulight launches a product family for photodynamic therapy »

29 Aug 2013Modulight launches a turnkey OEM laser system platform to photodynamic therapy »

20 Jun 2013Kalle Palomaki nominated to Modulight Board »

28 Jan 2013Modulight launches new 1W RGB LimeLight laser modules with the smallest form factor in the industry »

01 Nov 2012Medical Design Briefs: Therapeutic Laser Systems Improve Quality of Life and Save in Healthcare »

17 Apr2012Modulight receives a contract for manufacturing CE certified medical laser systems for cancer therapy »

15 Nov 2011Modulight expands LimeLight product family with blue wavelength »

06 Oct 2011Modulight receives ISO 13485:2003 certification for medical laser manufacturing »

19 May 2011Modulight releases multi-chip red laser modules for industrial, display and medical applications »

20 Jan 2011LimeLight laser systems on display in Photonics West at booth #4635 »

13 Jan 2011Modulight adds features and scales up power from FiberLight product platform »

11 Nov 2010Modulight releases OEM laser systems for medical and industrial applications »

16 Sep 2010Modulight releases high-power single-mode lasers at 1310-1650nm for OTDR »

25 Aug 2010Modulight celebrates 10 years anniversary with 35% growth in business »

26 May 2010Modulight welcomes summer by releasing a series of colourful and powerful mounted single-emitters »

30 Apr 2010Modulight appoints new partners in Italy and Singapore »


2008–2009

10 Dec 2009Modulight turning Christmas all red, by adding new red lasers to ChiliLase product »

21 Oct 2009Modulight lasers launched to space on ESA’s SMOS satellite mission »

06 Oct 2009Modulight appoints distribution partner in the United Kingdon and Republic of Ireland »

20 May 2009Modulight establishes distribution partner in China and wins new contract for laser display application »

14 May 2009Modulight celebrates spring by releasing a series of colourful Butterfly lasers »

02 Apr 2009Modulight announces 7 Watt 635nm Conduction Cooled Diode Laser; Applications include Laser Display, Medical, and Illumination »

26 Jan 2009Modulight “FiberLight”, the platform for fiber-coupled high-power lasers from 635 nm to 1550 nm »

14 Nov 2008Modulight introduces “SparkLight”, the turnkey platform for high-power lasers »

06 Nov 2008Modulight scales up power to 20 W at 1470 nm »

11 Sep 2008Modulight receives 2008 Frost & Sullivan Award for North American Laser Diode Emerging Company of the Year »

04 Sep 2008A new generation of high-power collimated laser modules shines from Modulight »

28 Aug 2008Modulight introduces 1470 nm high-power lasers »

19 Jun 2008Modulight introduces 830 nm high-power lasers »

29 May 2008Modulight to continue supply agreement with Vaisala for meteorological applications »

08 May 2008Modulight to develop high-brightness pump laser technology for European Space Agency »

06 Mar 2008Modulight’s RangerLase provides up to 20 W laser power at 1550 nm »

01 Feb 2008ROAD MONITORING: Laser systems monitoring slipperiness of roadways (Laser Focus World, February 2008) »




Newsletters archive